Codagenix Inc. is pioneering a synthetic biology-based platform that integrates live-attenuated virus design with advanced codon deoptimization technology. This innovative approach allows for the precise and stable modification of viral genomes, enabling the rapid development of vaccine and therapeutic candidates for infectious diseases and cancer. By designing multiple vaccine candidates simultaneously, Codagenix can significantly reduce the time required to transition from the genetic sequence of a virus to viable vaccine candidates, addressing urgent global health threats more efficiently than traditional methods.

The company’s pipeline includes a range of vaccine candidates targeting various infectious diseases, such as COVID-19, RSV, influenza, yellow fever, dengue, and Zika, as well as virotherapeutics for cancer treatment. Codagenix's vaccines are designed to elicit broad immune responses while ensuring safety and scalability, with some candidates demonstrating promising results in preclinical and clinical trials. Additionally, the company is focused on improving animal health through vaccines that enhance the well-being of livestock and companion animals, thereby contributing to global food security and reducing reliance on antibiotics.

United States

Codagenix Inc. is a clinical stage biotechnology company with vaccine products against influenza, respiratory syncytial virus, dengue virus, and others currently under development. Codagenix uses a computer-based algorithm, called SAVE (Synthetic Attenuated Virus Engineering) to design viral genomes that are identical to the wild type strain at the amino acid level, but make less protein in human cells. The highly attenuated viruses make excellent vaccines or oncolytics against solid tumors. Codagenix represents the next wave in vaccine technology, untethered from traditional, time-consuming and unpredictable approaches to attenuating viruses.

Cancer

Infectious Diseases

Codagenix Inc.

COVID-19

CoviLiv

Biologics

Vaccines

Respiratory syncytial virus

RSV CodaVax [Adult]

Influenza

Universal influenza CodaVaxTM – H1N1

RSV CodaVax [Pediatric]

Yellow fever

Vaccine

dengue

CDX-DENV

Zika virus infection

CDX-ZiKV

Breast cancer

CodaLytic

Solid tumor/s

CDX-Onc

New York

Antiviral Therapies

Cell Therapies

Gene Therapy

Immuno-Oncology

Therapeutic

Codagenix Inc.

Company Details